176 related articles for article (PubMed ID: 16316309)
41. Clofarabine: past, present, and future.
Kantarjian HM; Jeha S; Gandhi V; Wess M; Faderl S
Leuk Lymphoma; 2007 Oct; 48(10):1922-30. PubMed ID: 17852710
[TBL] [Abstract][Full Text] [Related]
42. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
[TBL] [Abstract][Full Text] [Related]
43. Clofarabine in the treatment of poor risk acute myeloid leukaemia.
Krawczyk J; Ansar N; Swords R; Murphy T; MacDonagh B; Meenaghan T; Hayden P; Hayad A; Murray M; O'Dwyer M
Hematol Oncol; 2010 Sep; 28(3):118-23. PubMed ID: 19768694
[TBL] [Abstract][Full Text] [Related]
44. Clofarabine for the treatment of adult acute myeloid leukemia.
Thomas X; Raffoux E; Elhamri M; Lobe I; Cannas G; Dombret H
Future Oncol; 2009 Oct; 5(8):1197-210. PubMed ID: 19852733
[TBL] [Abstract][Full Text] [Related]
45. Clofarabine Dosing in a Patient With Acute Myeloid Leukemia on Intermittent Hemodialysis: Case Report and Review of the Literature.
Benitez LL; Gharibian K; Frame D; Mody R; Mora E
J Pediatr Hematol Oncol; 2017 Aug; 39(6):481-484. PubMed ID: 28538504
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR
Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461
[TBL] [Abstract][Full Text] [Related]
47. Clofarabine: new drug. Children with acute lymphoblastic leukaemia: a last resort.
Prescrire Int; 2007 Dec; 16(92):238-9. PubMed ID: 18092403
[TBL] [Abstract][Full Text] [Related]
48. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Kantarjian H; Gandhi V; Cortes J; Verstovsek S; Du M; Garcia-Manero G; Giles F; Faderl S; O'Brien S; Jeha S; Davis J; Shaked Z; Craig A; Keating M; Plunkett W; Freireich EJ
Blood; 2003 Oct; 102(7):2379-86. PubMed ID: 12791647
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms of anti-cancer action and pharmacology of clofarabine.
Zhenchuk A; Lotfi K; Juliusson G; Albertioni F
Biochem Pharmacol; 2009 Dec; 78(11):1351-9. PubMed ID: 19576186
[TBL] [Abstract][Full Text] [Related]
50. Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia.
Baytan B; Ozdemir O; Gunes AM; Dönmez O
J Pediatr Hematol Oncol; 2010 Mar; 32(2):144-6. PubMed ID: 20057324
[TBL] [Abstract][Full Text] [Related]
51. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett AK; Russell NH; Kell J; Dennis M; Milligan D; Paolini S; Yin J; Culligan D; Johnston P; Murphy J; McMullin MF; Hunter A; Das-Gupta E; Clark R; Carr R; Hills RK
J Clin Oncol; 2010 May; 28(14):2389-95. PubMed ID: 20385984
[TBL] [Abstract][Full Text] [Related]
52. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
[TBL] [Abstract][Full Text] [Related]
53. Clofarabine in the treatment of myelodysplastic syndromes.
Bryan J; Kantarjian H; Prescott H; Jabbour E
Expert Opin Investig Drugs; 2014 Feb; 23(2):255-63. PubMed ID: 24410313
[TBL] [Abstract][Full Text] [Related]
54. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Faderl S; Gandhi V; Keating MJ; Jeha S; Plunkett W; Kantarjian HM
Cancer; 2005 May; 103(10):1985-95. PubMed ID: 15803490
[TBL] [Abstract][Full Text] [Related]
55. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Larson RA
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
[TBL] [Abstract][Full Text] [Related]
56. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
57. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
58. Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases.
Chiao N; Bumgardner A; Duvic M
Leuk Lymphoma; 2003 Aug; 44(8):1405-7. PubMed ID: 12952235
[TBL] [Abstract][Full Text] [Related]
59. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
Bagley RG; Roth S; Kurtzberg LS; Rouleau C; Yao M; Crawford J; Krumbholz R; Lovett D; Schmid S; Teicher BA
Int J Oncol; 2009 May; 34(5):1329-40. PubMed ID: 19360345
[TBL] [Abstract][Full Text] [Related]
60. Nelarabine in the treatment of refractory T-cell malignant diseases.
Kline J; Larson RA
Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
